Acurx Pharmaceuticals Inc Ordinary Shares ACXP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ACXP is a good fit for your portfolio.
News
-
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
-
Acurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business Update
-
Acurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU Development
-
New to The Street Announces Line-up of its Corporate Interviews Airing on its Leadership and Business Televised Series
-
New to The Street Airs Episode 556 Featuring Five Corporate Interviews, Broadcast on the FOX Business Network Monday, February 19, 2024, at 10:30 PM PT
-
New to The Street Announces its 553rd Episode TV Line Up, Featuring Five Corporate Guests, Airing on the FOX Business Network, Monday, February 5, 2024, 10:30 PM PT
-
New to The Street TV Announces Episode #552 with its Five Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Tonight, February 1, 2024, at 9:30 PM PT
-
Acurx Announces Positive Extended Clinical Cure Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients
Trading Information
- Previous Close Price
- $2.33
- Day Range
- $2.36–2.48
- 52-Week Range
- $1.17–8.82
- Bid/Ask
- $2.40 / $2.45
- Market Cap
- $38.60 Mil
- Volume/Avg
- 84,623 / 176,380
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 4
- Website
- https://www.acurxpharma.com
Valuation
Metric
|
ACXP
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.61 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
ACXP
|
---|---|
Quick Ratio | 2.50 |
Current Ratio | 2.53 |
Interest Coverage | — |
Quick Ratio
ACXP
Profitability
Metric
|
ACXP
|
---|---|
Return on Assets (Normalized) | −139.13% |
Return on Equity (Normalized) | −47.66% |
Return on Invested Capital (Normalized) | −207.17% |
Return on Assets
ACXP
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Thkkjxdn | Prgr | $570.1 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xcjlzyd | Yknvwjg | $108.0 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Wprzdzpx | Yyxcxf | $105.6 Bil | |
MRNA
| Moderna Inc | Vpprkyr | Jxhb | $40.8 Bil | |
ARGX
| argenx SE ADR | Jjgcdsrz | Jcqm | $23.5 Bil | |
BNTX
| BioNTech SE ADR | Vzjwxwdp | Rnhz | $21.9 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Srydvrrv | Pcgnl | $18.8 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Cjzzdgcg | Bsqjlv | $16.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Chdjzbckvt | Nzqklph | $13.6 Bil | |
INCY
| Incyte Corp | Lcvysjg | Fkfvxqf | $12.8 Bil |